Intravenous Epoprostenol Dosing Regimen
Start epoprostenol at 1-2 ng/kg/min via continuous IV infusion through a central venous catheter, titrate upward by 1-2 ng/kg/min increments every 15 minutes or longer based on tolerance, and expect maintenance doses typically between 20-40 ng/kg/min, though individual requirements vary widely. 1, 2
Starting Dose
The initial infusion rate is 2 ng/kg/min 2. If this starting dose is not tolerated, use a lower dose of 1 ng/kg/min 1. The drug must be administered through a tunneled central venous catheter due to its 6-minute half-life and effects on peripheral veins 1.
Acute Titration Phase (First 24-48 Hours)
During initial dose-finding:
- Increase by 2 ng/kg/min increments every 15 minutes or longer until dose-limiting side effects occur or further increases are not clinically warranted 2
- Monitor standing and supine blood pressure and heart rate for several hours after each dose adjustment 2
- Common dose-limiting effects include nausea, vomiting, hypotension, headache, and abdominal pain 1, 2
In clinical trials, patients reached a mean dose of 4.1 ng/kg/min by day 7 2.
Chronic Titration Schedule
After establishing initial tolerance:
- Increase by 1-2 ng/kg/min increments at intervals of at least 15 minutes, though intervals of 24-48 hours or longer are typical in practice 1, 2
- Base increases on persistence, recurrence, or worsening of pulmonary hypertension symptoms 2
- In the pivotal 12-week trial, the mean dose increased from 2.2 ng/kg/min at baseline to 11.2 ng/kg/min at week 12, with mean incremental increases of 2-3 ng/kg/min every 3 weeks 2
Maintenance Dose
Most patients reach a "plateau" dose between 20-40 ng/kg/min, though the range shows considerable interindividual variability 1. Some patients require doses well above or below this range. In pediatric populations, effective doses are frequently higher, averaging around 80 ng/kg/min with a range of 40 to >150 ng/kg/min 3.
Recent evidence suggests that rapid and high-dose titration (achieving ≥20 ng/kg/min at 3 months and ≥45 ng/kg/min at 1 year) is associated with better hemodynamic improvement and survival compared to slower titration strategies 4. The rapid increase group showed 100% survival at 9.5 years versus 64% in the slow increase group.
Dose Adjustments
Downward titration:
- Decrease gradually in 2 ng/kg/min decrements every 15 minutes or longer until dose-limiting effects resolve 2
- Dose-dependent side effects (headache, flushing, jaw pain, diarrhea, nausea, musculoskeletal pain) often respond to cautious dose reduction 1
Critical Safety Considerations
Never abruptly discontinue or make sudden large reductions in epoprostenol infusion 1, 2. Patients with severe disease can experience:
- Clinical deterioration within 20-30 minutes of infusion interruption 1
- Rebound worsening of pulmonary hypertension with symptomatic deterioration and potential death 1, 5
Patients must carry spare premixed cassettes and a backup infusion pump at all times 1. If central access is lost, immediately access emergency medical services and re-establish infusion via peripheral IV until central access is restored 1.
Administration Requirements
- Continuous IV infusion via tunneled central venous catheter using ambulatory infusion pump 1, 2
- Keep solution cold with ice packs during infusion (drug unstable at room temperature with 6-minute half-life) 1
- Use 0.22 micron in-line filter 2
- Do not mix with any other parenteral medications or solutions 2
- Reconstitute only with Sterile Water for Injection or Sodium Chloride 0.9% Injection 2
Monitoring During Titration
Observe patients closely during dose adjustments for:
- Acute overdose signs: systemic hypotension 1
- Chronic overdose signs: hyperdynamic state and high-output cardiac failure 1
- Therapeutic response: improved exercise capacity, functional class, and hemodynamics 1, 5
Given the complexity of administration and need for considerable infrastructure, strongly consider referring patients to centers of excellence in pulmonary hypertension with experienced nurses and physicians 1.